Class 3 Device Recall VITROS Chemistry Products Cl Slides

• Date Initiated by Firm: July 11, 2018
• Create Date: September 14, 2018
• Recall Status: Terminated on August 11, 2020
• Recall Number: Z-3043-2018
• Recall Event ID: 80697
• 510(K)Number: K071801
• Product Classification: Electrode, ion-specific, chloride - Product Code CGZ
• Product: VITROS Chemistry Products Cl- Slides, Product Code 844 5207; ; Product Usage: For in vitro diagnostic use only. VITROS Chemistry Products Cl- Slides quantitatively measure chloride (Cl-) concentration in serum and plasma using VITROS 250/350/5,1 FS and 4600 Chemistry Systems and the VITROS 5600 Integrated System.
• Code Information: GEN 5 and below
• Recalling Firm/ Manufacturer: Ortho-Clinical Diagnostics; 100 Indigo Creek Dr; Rochester NY 14626-5101
• Manufacturer Reason for Recall: The slides do not meet the maximum allowable interference (MAI) claims for triglyceride interference when using serum samples. Triglyceride interference on the Cl- Slide was observed around a triglyceride concentration 600mg/dL, however the current triglyceride interference claim states interference should not occur below 800mg/dL of triglyceride.
• FDA Determined Cause: Under Investigation by firm
• Action: On 7/11/18, Important Product Correction Notification letters were distributed to customers. The letters instructed customers to perform the following actions: VITROS Cl- Slides and VITROS CREA Slides Instructions for Use will be updated to contain the revised information described in this letter; we will notify you upon availability. In the interim, retain a copy of this customer letter for your records. Calibration Diskette and ADD Data Release Version (DRV) 5992 (and above) will support the revised measuring range for VITROS CREA Slides. We anticipate that DRV 5992 will be available beginning on July 28, 2018 by eConnectivity or will be sent via your normal Cal Disk or ADD mailing. Prior to the availability of the revised IFU, be aware that if a serum or plasma sample contains a Triglyceride concentration of 600 mg/dL or higher, the Chloride result may be positively biased by approximately 2.1 mmol/L. Follow your normal laboratory procedures as you would for other known assay interferences. Note: It is acceptable to continue using VITROS Cl- Slides. Upon availability, install the Calibration Diskette or ADD to implement the revised Measuring Range: For VITROS 4600, 5600 or 5,1 FS Systems: Install ADD DRV 5992 or above, Select All Assay Data option For VITROS 250/350 Systems: Install Calibration Diskette DRV 5992 or above Refer to the enclosure for additional instructions to update the Measuring Range. Update laboratory procedures and your Laboratory Information System (LIS), as necessary. Retain this letter until we send a notification to alert you when the revised IFUs are available. Complete the Confirmation of Receipt form and return by July 25, 2018. Post this notification by each system that processes VITROS Cl- or CREA Slides. Forward this notification if the product was distributed outside of your facility.
• Quantity in Commerce: 128196
• Distribution: Worldwide Distribution - US Nationwide and in the countries of: Australia, Belgium, Bermuda, Brazil, Canada, Chile, China, Columbia, Denmark, France, Germany, India, Italy, Japan, Mexico, Norway, Poland, Portugal, Russia, Singapore, Spain, Sweden, The Netherlands, and United Kingdom.
• Total Product Life Cycle: TPLC Device Report

¹ A record in this database is created when a firm initiates a correction or removal action. The record is updated if the FDA identifies a violation and classifies the action as a recall, and it is updated for a final time when the recall is terminated. Learn more about medical device recalls.
² Per FDA policy, recall cause determinations are subject to modification up to the point of termination of the recall.
³ For details about termination of a recall see Code of Federal Regulations (CFR) Title 21 §7.55.

• 510(K) Database: 510(K)s with Product Code = CGZ and Original Applicant = Ortho-Clinical Diagnostics, Inc.